These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

45 related items for PubMed ID: 1710742

  • 1. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis.
    Mikhailidis DP, Mathur S, Barradas MA, Dandona P.
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():platelet inhib/pd/ad/ae. PubMed ID: 1710742
    [Abstract] [Full Text] [Related]

  • 2. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S, Barradas MA, Mikhailidis DP, Dandona P.
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [Abstract] [Full Text] [Related]

  • 3. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
    Durrington PN, Winocour PH, Bhatnagar D.
    J Cardiovasc Pharmacol; 1990 Jul; 16 Suppl 9():S30-4. PubMed ID: 1710743
    [Abstract] [Full Text] [Related]

  • 4. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
    Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y.
    Metabolism; 2001 Apr; 50(4):477-80. PubMed ID: 11288046
    [Abstract] [Full Text] [Related]

  • 5. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
    Alberti KG, Jones IR, Laker MF, Swai AB, Taylor R.
    J Cardiovasc Pharmacol; 1990 Apr; 16 Suppl 9():S21-4; discussion S24-5. PubMed ID: 1710741
    [Abstract] [Full Text] [Related]

  • 6. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Apr; 11(3):331-40. PubMed ID: 2743372
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 8. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S.
    Circulation; 2004 May 11; 109(18):2197-202. PubMed ID: 15123532
    [Abstract] [Full Text] [Related]

  • 9. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J, Schwartz S, Brunner D.
    Arzneimittelforschung; 1994 Nov 11; 44(11):1217-22. PubMed ID: 7893284
    [Abstract] [Full Text] [Related]

  • 10. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
    Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S.
    Eur Heart J; 2005 Oct 11; 26(19):2032-8. PubMed ID: 15872029
    [Abstract] [Full Text] [Related]

  • 11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 11; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 12. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
    Hollenbeck CB, Johnston P, Varasteh BB, Chen YD, Reaven GM.
    Diabete Metab; 1991 Oct 11; 17(5):483-9. PubMed ID: 1752350
    [Abstract] [Full Text] [Related]

  • 13. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L, Behar S, Caspi A, Reshef N, Boyko V, Knobler H.
    Am Heart J; 2004 Feb 11; 147(2):239-45. PubMed ID: 14760320
    [Abstract] [Full Text] [Related]

  • 14. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.
    Riccardi G, Genovese S, Saldalamacchia G, Patti L, Marotta G, Postiglione A, Rivellese A, Capaldo B, Mancini M.
    Atherosclerosis; 1989 Feb 11; 75(2-3):175-81. PubMed ID: 2653325
    [Abstract] [Full Text] [Related]

  • 15. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.
    Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg M, Matas Z, Motro M, Tenenbaum A.
    Atherosclerosis; 2007 Sep 11; 194(1):265-71. PubMed ID: 16970952
    [Abstract] [Full Text] [Related]

  • 16. Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.
    Krysiak R, Okopien B.
    J Clin Pharmacol; 2011 Oct 11; 51(10):1459-67. PubMed ID: 21119093
    [Abstract] [Full Text] [Related]

  • 17. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM.
    Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG.
    Diabetes Care; 1990 Aug 11; 13(8):855-63. PubMed ID: 2209320
    [Abstract] [Full Text] [Related]

  • 18. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
    Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, Anderson DC.
    Diabet Med; 1990 Aug 11; 7(8):736-43. PubMed ID: 2147637
    [Abstract] [Full Text] [Related]

  • 19. Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients.
    Krysiak R, Gdula-Dymek A, Okopień B.
    Pharmacol Rep; 2011 Aug 11; 63(3):763-71. PubMed ID: 21857087
    [Abstract] [Full Text] [Related]

  • 20. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
    Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, Franceschini G, Sirtori CR, Tremoli E.
    Eur J Clin Pharmacol; 1992 Aug 11; 43(3):219-23. PubMed ID: 1425883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.